Interview: AstraZeneca ‘Is More Than Oncology’
AZ’s BioPharma Unit Head Points To CVRM And Respiratory Promise
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”
